LUTETIUM-177 PSMA THERAPY (200 mCi)
₹250000
Advanced Lutetium-177 PSMA Therapy is available at Molecular Diagnostics and Therapy, which is accredited by NABL and NABH. Targeted radionuclide therapy (Lutetium-177 PSMA Therapy) is a specific type of targeted treatment the doctor may use for selected prostate cancer patients. The PSMA protein is present on the surface of prostate cancer cells in higher quantities. The therapy involves the use of Lutetium-177, which is linked to a molecule that recognizes and binds to PSMA used by cancer cells. When it reaches these cells, the radioactive element emits radiation, which causes damage to cancer cells and inhibits their growth. The therapy is generally recommended for evaluation with a nuclear medicine specialist and review of prior imaging and/or clinical reports in men with advanced prostate cancer.
Common Reasons for Lutetium-177 PSMA Therapy
- Treatment of selected patients with advanced prostate cancer
- Prostate cancer that has spread to other parts of the body
- Prostate cancer that has progressed despite previous treatments
- Evaluation for targeted radionuclide therapy based on PSMA PET-CT findings
- Management of selected cases of metastatic castration-resistant prostate cancer
- Patients for whom conventional treatment options have become less effective or are unsuitable
Conditions Evaluated Before Therapy
PSMA Expression
PSMA PET-CT is frequently used to determine if there is adequate PSMA expression on prostate cancer cells. This can help the doctor determine if Lutetium-177 PSMA Therapy may benefit the patient.
Extent of Prostate Cancer
Imaging tests are used to learn more about the area and extent of cancer, such as whether the lymph nodes, bones, or other organs have become part of the cancer.
Kidney Function
Kidneys are a key part in eliminating the radioactive material. Before therapy, kidney function should be assessed in order to determine the suitability of therapy.
Blood Cell Counts
Blood tests are done to check the levels of haemoglobin, white blood cells, and platelets. The results enable physicians to determine if the patient is safe to receive treatment.
Overall Health Status
To find the right approach for the patient, the patient's previous treatments, current medications, symptoms, and overall health are reviewed prior to treatment.
Who Should Consider This Therapy?
Your doctor may consider Lutetium-177 PSMA Therapy if you have:
- Advanced or metastatic prostate cancer
- Prostate cancer that has progressed after previous treatments
- PSMA-positive findings on PET-CT imaging
- Disease that requires further treatment options
- A medical condition for which targeted radionuclide therapy may be suitable
The final decision depends on PSMA PET-CT findings, blood test results, kidney function, previous treatments, and overall clinical condition.
Benefits of Lutetium-177 PSMA Therapy
- Targets prostate cancer cells expressing PSMA
- Delivers radiation directly to targeted cancer sites
- May help control the growth of advanced prostate cancer
- Can be considered when certain previous treatments have not provided sufficient benefit
- May help reduce cancer-related symptoms in selected patients
- Provides a targeted treatment option for eligible patients
- Supports personalised cancer treatment planning
Why Choose Molecular Diagnostics and Therapy?
- Experienced nuclear medicine professionals
- Advanced nuclear medicine facilities
- NABL & NABH Accredited Diagnostic Centre
- Patient-focused treatment protocols
- Detailed evaluation before therapy
- Careful monitoring during the treatment process
- Transparent and affordable diagnostic and treatment services
- Comprehensive Radiology, Nuclear Medicine, and Pathology services under one roof
Book Lutetium-177 PSMA Therapy (200 mCi)
Select Molecular Diagnostics and Therapy, professional evaluations, and patient-centered nuclear medicine care for Lutetium-177 PSMA Therapy (200 mCi). Before determining the suitability of treatment, the patient's medical history, PSMA PET-CT scan results, and relevant lab reports are reviewed by our team. Therapy is properly carried out by qualified professionals in nuclear medicine, with safety concerns and any necessary follow-up suggested.
Test information: Fasting: As advised by the nuclear medicine specialist. Pre-therapy evaluation and required investigations are necessary.
Reporting: Not applicable. Treatment and follow-up are scheduled as advised by the nuclear medicine specialist.
- Complete the pre-therapy evaluation as advised by the nuclear medicine specialist.
- Bring your PSMA PET-CT scan reports, previous treatment records, and relevant medical documents.
- Blood tests, including complete blood count and kidney function tests, may be required before therapy.
- Inform the doctor about all current medications, allergies, and existing medical conditions.
- Inform the medical team if you have recently received chemotherapy, radiotherapy, or any other cancer treatment.
- Follow the specialist's instructions regarding fasting and fluid intake before therapy.
- Inform the doctor if you are pregnant or if pregnancy is possible in your household, as radiation safety precautions may be required.
- Follow all radiation safety instructions provided by the nuclear medicine team after treatment.
- Attend scheduled follow-up appointments and investigations as recommended by your specialist.
Talk to Health Expert
Health Articles
